OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)

Inclusion Criteria: * Aged 18～75 years (including 18 and 75)old at the time of signing Informed Consent Form * pMN patients diagnosed according to renal biopsy (original biopsy needs to include light, immunofluorescence, and electron microscopy) within 5 years or serum anti-PLA2R antibody (≥14 RU/ml ) * 24-hour UPCR ≥ 4 g/g and serum albumin (sALB) \< 30 g/L,despite being treated with ACEi and/or ARB for ≥ 6 months prior to screening, or 24-hour UPCR ≥ 5 g/g and sALB \< 30 g/L , despite being treated with ACEi and/or ARB for ≥ 3 months prior to screening; or 24-hour UPCR ≥ 8 g/g and sALB \< 25 g/L, despite being treated with ACEi and/or ARB for ≥ 1 month prior to screening,. * eGFR ≥40 mL/min/1.73m2 (CKD-EPI), a renal biopsy is required to exclude renal damage due to other co-morbidities if eGFR \<60mL/min/1.73 m2. * Ability to comply with the study protocol, in the investigator's judgment Exclusion Criteria: * Patients with a secondary cause of MN (e.g. hepatitis B, systemic lupus erythematosus, medications, malignancies) * Type 1 or 2 diabetes mellitus * eGFR \<40 mL/min/1.73m2 (CKD-EPI) or dialysis or kidney transplantation * Evidence of 50% reduction in proteinuria or serum anti-PLA2R antibody within 6 months prior to screening